Drug Trial Radar · NCT00116688
Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Last checked: Nov 20, 2026Latest source record: Dec 18, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
313
Actual
Start
Aug 2004
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. Participants must have previously completed a romiplostim ITP study.
Conditions
- Thrombocytopenia
- Idiopathic Thrombocytopenic Purpura
Interventions
RomiplostimBiological
Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: Duration of treatment plus 8 weeks (up to 285 weeks)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.